German China

Bioprocessing Thermo Fisher Scientific Sets Up 160-Million-Dollar Biomanufacturing Unit in USA

Source: Press release Thermo Fisher Scientific

Related Vendor

The mega biomanufacturing facility will cater to the growing demand for biologic materials and is part of the company’s 650-million-dollar multi-year investment strategy which aims to expand its bioprocessing production capabilities.

The technologies produced at the Chelmsford site are used in the purification process of developing biotherapeutics and vaccines.
The technologies produced at the Chelmsford site are used in the purification process of developing biotherapeutics and vaccines.
(Source: ©copyright John Still for Thermo Fisher Scientific)

Waltham/USA – Thermo Fisher Scientific recently inaugurated a new biomanufacturing facility in Chelmsford, Massachusetts, USA. The 160 million dollar, 85,000-square-foot facility will help meet growing demand for the biologic materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher’s 650-million-dollar multi-year investment to expand its bioprocessing production capabilities.

The technologies produced at the Chelmsford site are used in the purification process of developing biotherapeutics and vaccines. These products help save time and reduce costs so that new treatments can reach more patients faster. With the opening of the site in Chelmsford, Thermo Fisher continues to bring its capacity investments online to support customers as they grow and scale.

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

Jean Luo, vice president and general manager, purification and pharma analytics, Thermo Fisher Scientific said, “The Chelmsford site will help us provide our customers with the critical resin materials they need as they scale up production and bring new innovations to market. This ultimately helps ensure more patients get the treatments they need faster.”

When fully staffed, the Chelmsford site will employ up to 250 people in roles across manufacturing, engineering, procurement, quality, warehousing, site leadership and more. This site is part of Thermo Fisher’s global bioprocessing supply network that spans across 100 countries and helps ensure critical medicines reach patients.

(ID:48590212)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent